Description

---

​Part 1.- Definition, epidemiology, and pathogenesis
.- Chapter 1: Definition of IPF (Question: Is the latest classification ATS/ERS] satisfactory?).- Chapter 2: Epidemiology and risk factors of IPF (Question: Can we dare to ask, "What are the possible causes?").- Chapter 3: Acute exacerbation of IPF (Question: The concept was proposed in Japan, but why was it not recognized in western countries?).- Chapter 4: Pathogenesis (Question: Is abnormal repair of epithelial damage involved in the basic pathogenesis of this disease?)
.- Part 2 Diagnosis
.- Chapter 5: Specific serum markers of IPF (Question: What are the significances of KL-6, SP-A, and SP-D?).- Chapter 6: High-resolution CT of honeycombing and IPF/UIP (Question: To what extent can honeycomb lung be diagnosed by imaging? To what extent can IPF diagnosis be made by HRCT?).- Chapter 7: Pathology of IPF (Question: Why does the pathological classification of IIPs vary among pathologists?).- Chapter 8: Differential diagnosis (Question: What should we particularly keep in mind in the differential diagnosis?)
.- Part 3 Management and prognosis
.- Chapter 9 Pharmacotherapy of IPF (antifibrotic compounds) (Question: Can antifibrotic agents really inhibit fibrosis? How about the development of new therapeutic agents?).- Chapter 10: Pharmacotherapy of IPF (Corticosteroids, immunosuppressants) (Question: Are these actually effective? Ineffective? Harmful?).- Chapter 11: Non-pharmacological therapy for IPF (Question: Is respiratory care actually effective?).- Chapter 12: Pharmacotherapy of acute exacerbation of IPF (Corticosteroids, immunosuppressants and direct hemoperfusion with polymyxin B) (Question: Are high-dose steroid therapy, other immunosuppressant therapy, and PMX therapy often used in Japan] really effective?)
.- Part 4 Topics
.- Chapter 13: Combined pulmonary fibrosis and emphysema (CPFE) (Question:

Is it an independent disease entity?).- Chapter 14: Common pathways in IPF and lung cancer (Question: Why is lung cancer associated with IPF at a high frequency?).- Chapter 15: Acute exacerbation of IIPs after pulmonary resection for lung cancer (Question: Can acute exacerbation of IPF be predicted preoperatively?)

About the Author

---

Hiroyuki Nakamura, MD, PhD.Department of Respiratory Medicine, Tokyo Medical University Ibaraki Medical Center, JapanKazutetsu Aoshiba, MD, PhD.Department of Respiratory Medicine, Tokyo Medical University Ibaraki Medical Center, Japan